High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants

Xinyuan Chen; Marco Pravetoni; Brijesh Bhayana; Paul R. Pentel; Mei X. Wu

doi:10.1016/j.vaccine.2012.10.069

High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants

Xinyuan Chen, Marco Pravetoni, Brijesh Bhayana, Paul R. Pentel, Mei X. Wu

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Abstract

Immunotherapy for tobacco addiction may offer a safe, alternative treatment if the immunogenicity of the current nicotine vaccines can be improved. We show here that intradermal (ID) immunization induces the production of antibody directed against nicotine (NicAb) at a much higher level than conventional intramuscular (IM) immunization. The magnitude and duration of NicAb production was further increased robustly by non-inflammatory laser vaccine adjuvant (LVA), slightly inflammatory monophosphoryl lipid A (MPL) or a combination of MPL and CpG adjuvants. Consequently, significantly fewer vaccination doses were required to attain a high level of NicAb production for an extended period of time and reduce nicotine entry into the brain in the presence of LVA, MPL or MPL/CpG adjuvant, respectively. Yet, the potency of these adjuvants to augment ID nicotine vaccine immunogenicity came at the expense of local skin reactogenicity, with LVA causing little skin reaction and MPL/CpG stimulating overt skin irritation. These observations underscore a necessity of a balance between optimal adjuvant potency and undesired local reactogenicity. In summary, our study presents a novel approach to significantly improve nicotine vaccine immunogenicity by a combination of safe cutaneous vaccine adjuvants with ID immunization.

Original language	English (US)
Pages (from-to)	159-164
Number of pages	6
Journal	Vaccine
Volume	31
Issue number	1
DOIs	https://doi.org/10.1016/j.vaccine.2012.10.069
State	Published - Dec 17 2012
Externally published	Yes

Bibliographical note

Funding Information:
We would like to thank Ms. Florence Lin, Dr. Xiao-Ming Lu, Dr. Yong-Ming Yu, and Dr. Alan J. Fischerman (Department of Surgery, Massachusetts General Hospital) for assistance in setting up gas chromatography–mass spectrometry (GC–MS) method for nicotine detection in our preliminary studies, Zhanliang Wei to collect blood and measure NicAb titer by ELISA, and Theresa Harmon (Departments of Pharmacology and Medicine, University of Minnesota Medical School) for measurement of brain and serum nicotine concentrations. This work was supported by the National Institutes of Health Grants AI070785 and RC1 DA028378 (M.X.W.) and DA10714 (P.R.P.).

Keywords

Addiction
Adjuvant
Immunogenicity
Immunotherapy
Intradermal delivery
Nicotine vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.vaccine.2012.10.069

OpenUrl availability

Full text

Cite this

@article{becd84b2217c4e538f24818c3c310adf,

title = "High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants",

abstract = "Immunotherapy for tobacco addiction may offer a safe, alternative treatment if the immunogenicity of the current nicotine vaccines can be improved. We show here that intradermal (ID) immunization induces the production of antibody directed against nicotine (NicAb) at a much higher level than conventional intramuscular (IM) immunization. The magnitude and duration of NicAb production was further increased robustly by non-inflammatory laser vaccine adjuvant (LVA), slightly inflammatory monophosphoryl lipid A (MPL) or a combination of MPL and CpG adjuvants. Consequently, significantly fewer vaccination doses were required to attain a high level of NicAb production for an extended period of time and reduce nicotine entry into the brain in the presence of LVA, MPL or MPL/CpG adjuvant, respectively. Yet, the potency of these adjuvants to augment ID nicotine vaccine immunogenicity came at the expense of local skin reactogenicity, with LVA causing little skin reaction and MPL/CpG stimulating overt skin irritation. These observations underscore a necessity of a balance between optimal adjuvant potency and undesired local reactogenicity. In summary, our study presents a novel approach to significantly improve nicotine vaccine immunogenicity by a combination of safe cutaneous vaccine adjuvants with ID immunization.",

keywords = "Addiction, Adjuvant, Immunogenicity, Immunotherapy, Intradermal delivery, Nicotine vaccine",

author = "Xinyuan Chen and Marco Pravetoni and Brijesh Bhayana and Pentel, {Paul R.} and Wu, {Mei X.}",

note = "Funding Information: We would like to thank Ms. Florence Lin, Dr. Xiao-Ming Lu, Dr. Yong-Ming Yu, and Dr. Alan J. Fischerman (Department of Surgery, Massachusetts General Hospital) for assistance in setting up gas chromatography–mass spectrometry (GC–MS) method for nicotine detection in our preliminary studies, Zhanliang Wei to collect blood and measure NicAb titer by ELISA, and Theresa Harmon (Departments of Pharmacology and Medicine, University of Minnesota Medical School) for measurement of brain and serum nicotine concentrations. This work was supported by the National Institutes of Health Grants AI070785 and RC1 DA028378 (M.X.W.) and DA10714 (P.R.P.).",

year = "2012",

month = dec,

day = "17",

doi = "10.1016/j.vaccine.2012.10.069",

language = "English (US)",

volume = "31",

pages = "159--164",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants

AU - Chen, Xinyuan

AU - Pravetoni, Marco

AU - Bhayana, Brijesh

AU - Pentel, Paul R.

AU - Wu, Mei X.

N1 - Funding Information: We would like to thank Ms. Florence Lin, Dr. Xiao-Ming Lu, Dr. Yong-Ming Yu, and Dr. Alan J. Fischerman (Department of Surgery, Massachusetts General Hospital) for assistance in setting up gas chromatography–mass spectrometry (GC–MS) method for nicotine detection in our preliminary studies, Zhanliang Wei to collect blood and measure NicAb titer by ELISA, and Theresa Harmon (Departments of Pharmacology and Medicine, University of Minnesota Medical School) for measurement of brain and serum nicotine concentrations. This work was supported by the National Institutes of Health Grants AI070785 and RC1 DA028378 (M.X.W.) and DA10714 (P.R.P.).

PY - 2012/12/17

Y1 - 2012/12/17

N2 - Immunotherapy for tobacco addiction may offer a safe, alternative treatment if the immunogenicity of the current nicotine vaccines can be improved. We show here that intradermal (ID) immunization induces the production of antibody directed against nicotine (NicAb) at a much higher level than conventional intramuscular (IM) immunization. The magnitude and duration of NicAb production was further increased robustly by non-inflammatory laser vaccine adjuvant (LVA), slightly inflammatory monophosphoryl lipid A (MPL) or a combination of MPL and CpG adjuvants. Consequently, significantly fewer vaccination doses were required to attain a high level of NicAb production for an extended period of time and reduce nicotine entry into the brain in the presence of LVA, MPL or MPL/CpG adjuvant, respectively. Yet, the potency of these adjuvants to augment ID nicotine vaccine immunogenicity came at the expense of local skin reactogenicity, with LVA causing little skin reaction and MPL/CpG stimulating overt skin irritation. These observations underscore a necessity of a balance between optimal adjuvant potency and undesired local reactogenicity. In summary, our study presents a novel approach to significantly improve nicotine vaccine immunogenicity by a combination of safe cutaneous vaccine adjuvants with ID immunization.

AB - Immunotherapy for tobacco addiction may offer a safe, alternative treatment if the immunogenicity of the current nicotine vaccines can be improved. We show here that intradermal (ID) immunization induces the production of antibody directed against nicotine (NicAb) at a much higher level than conventional intramuscular (IM) immunization. The magnitude and duration of NicAb production was further increased robustly by non-inflammatory laser vaccine adjuvant (LVA), slightly inflammatory monophosphoryl lipid A (MPL) or a combination of MPL and CpG adjuvants. Consequently, significantly fewer vaccination doses were required to attain a high level of NicAb production for an extended period of time and reduce nicotine entry into the brain in the presence of LVA, MPL or MPL/CpG adjuvant, respectively. Yet, the potency of these adjuvants to augment ID nicotine vaccine immunogenicity came at the expense of local skin reactogenicity, with LVA causing little skin reaction and MPL/CpG stimulating overt skin irritation. These observations underscore a necessity of a balance between optimal adjuvant potency and undesired local reactogenicity. In summary, our study presents a novel approach to significantly improve nicotine vaccine immunogenicity by a combination of safe cutaneous vaccine adjuvants with ID immunization.

KW - Addiction

KW - Adjuvant

KW - Immunogenicity

KW - Immunotherapy

KW - Intradermal delivery

KW - Nicotine vaccine

UR - http://www.scopus.com/inward/record.url?scp=84870506539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870506539&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.10.069

DO - 10.1016/j.vaccine.2012.10.069

M3 - Article

C2 - 23123021

AN - SCOPUS:84870506539

SN - 0264-410X

VL - 31

SP - 159

EP - 164

JO - Vaccine

JF - Vaccine

IS - 1

ER -

High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this